Prostate cancer is the most common non-skin cancer in men. Biomarker-driven research — from PSA-based screening to PSMA-targeted theranostics — is transforming diagnosis and treatment. abinScience provides validated antibodies, recombinant proteins, and biosimilar-grade reference proteins for the targets listed below. RUO
Download product datasheets, validation images (WB/IHC/IF/FC), CoA, and application protocols on each product page. All data is lot-specific.
We offer 58 detection antibodies, 59 research-grade biosimilar proteins, and 13 recombinant proteins. Validated applications include: Blocking, ELISA, FC, IF, IHC, WB. Available clones include: 22C3 (ELISA, FC, IHC, WB; APC, FITC, PE), Polyclonal (ELISA, IHC, WB; unconjugated), SP142 (ELISA, IHC, WB; unconjugated). Research-grade biosimilar proteins also available (e.g., Envafolimab, Pacmilimab, Cosibelimab).
We offer 60 detection antibodies, 9 research-grade biosimilar proteins, and 6 recombinant proteins. Validated applications include: Blocking, ELISA, FC, IHC, WB. Available clones include: Polyclonal (ELISA, IHC, WB; unconjugated), N430/20 (IHC, WB; unconjugated), N430/26 (IHC, WB; unconjugated). Research-grade biosimilar proteins also available (e.g., Avdoralimab, CD88/C5AR1 (ADC-1004), CD88/C5AR1 (MOR210)).
We offer 22 detection antibodies, 14 research-grade biosimilar proteins, and 13 recombinant proteins. Validated applications include: Blocking, ELISA, FC, IHC, SPR, WB. Available clones include: Polyclonal (ELISA, IHC, WB; unconjugated), 1A097 (ELISA, IHC, WB; unconjugated), 1A098 (ELISA, IHC, WB; unconjugated). Research-grade biosimilar proteins also available (e.g., Pasotuxizumab, HuJ591-Gsmab, Rosopatamab).
We offer 23 detection antibodies, 2 research-grade biosimilar proteins, and 2 recombinant proteins. Validated applications include: Blocking, ELISA, FC, IHC, SPR, WB. Available clones include: Polyclonal (ELISA, IHC, WB; unconjugated), 1A553 (ELISA, IHC, WB; unconjugated), 1A554 (ELISA, IHC, WB; unconjugated). Research-grade biosimilar proteins also available (e.g., Lanadelumab, Navenibart).
Yes — our parent company AtaGenix provides full custom antibody development from immunogen design through hybridoma production and characterization, including targets not yet in our catalog.
Human
ELISA, FCM, WB
Human
IgG1, kappa
SAA2012
Human
ELISA, FCM
Human
IgG1, kappa
SAA2216
Human
FCM
Human
IgG1, kappa
MN14
Human
FCM
Human
IgG1, kappa
RG7813
Human
FCM
Human
IgG1, kappa
4D5V8
Human
ELISA, FCM, IHC, WB
Human
IgG1
5E5#
Human
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Human
Fab Fused with a fragment of Pseudomonas exotoxin A.
LMB-100
Human
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Human
IgG
BMS 986148
Human
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Human
scFv-Human IgG1, kappa
MEDI4276
Human
ELISA, Bioactivity: FACS, Functional assay, Research in vivo
Human
IgG1-kappa
SGM 101